Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIANNASDAQ:PASGNASDAQ:QTTBNASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIANLianBio$0.36$0.22$0.27▼$4.99$38.90M0.231.04 million shs7,515 shsPASGPassage Bio$0.36+0.5%$0.36$0.26▼$1.33$22.36M1.68342,341 shs157,842 shsQTTBQ32 Bio$1.83+8.9%$1.74$1.38▼$53.79$22.32M-0.02196,571 shs253,283 shsSNGXSoligenix$1.93+1.0%$2.01$1.68▼$14.83$6.30M2.06760,607 shs12,277 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIANLianBio0.00%-3.34%+89.40%+86.17%+8.45%PASGPassage Bio-3.22%+13.97%+11.21%-29.78%-68.31%QTTBQ32 Bio+3.70%-5.08%-10.16%-28.21%-93.54%SNGXSoligenix+5.52%-3.05%-11.98%-16.23%-67.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLIANLianBioN/AN/AN/AN/AN/AN/AN/AN/APASGPassage Bio3.0344 of 5 stars3.53.00.00.03.31.71.3QTTBQ32 Bio2.8289 of 5 stars3.14.00.00.02.71.71.3SNGXSoligenix0.9377 of 5 stars0.04.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIANLianBio 0.00N/AN/AN/APASGPassage Bio 3.00Buy$7.501,984.49% UpsideQTTBQ32 Bio 2.25Hold$24.711,250.51% UpsideSNGXSoligenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SNGX, QTTB, LIAN, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025QTTBQ32 BioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/4/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIANLianBioN/AN/AN/AN/A$2.71 per shareN/APASGPassage BioN/AN/AN/AN/A$2.03 per shareN/AQTTBQ32 Bio-$6.65M-3.36N/AN/A$22.47 per share0.08SNGXSoligenix-$117.03K-53.83N/AN/A$3.83 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/APASGPassage Bio-$102.06M-$1.02N/AN/AN/AN/A-72.53%-52.10%8/14/2025 (Estimated)QTTBQ32 Bio-$112.96M-$4.94N/AN/AN/AN/A-146.18%-54.49%8/14/2025 (Estimated)SNGXSoligenix-$6.14M-$4.29N/AN/AN/A-1,473.38%-223.29%-74.18%8/8/2025 (Estimated)Latest SNGX, QTTB, LIAN, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/A5/9/2025Q1 2025SNGXSoligenix-$0.67-$1.06-$0.39-$1.06N/AN/A5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A3/21/2025Q4 2024SNGXSoligenix-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 million3/11/2025Q4 2024QTTBQ32 Bio-$1.25-$1.16+$0.09-$1.16N/AN/A3/4/2025Q4 2024PASGPassage Bio-$0.21-$0.20+$0.01-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLIANLianBioN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIANLianBioN/A10.0610.06PASGPassage BioN/A5.155.15QTTBQ32 Bio0.616.536.53SNGXSoligenixN/A2.282.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIANLianBio74.85%PASGPassage Bio53.48%QTTBQ32 Bio31.32%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipLIANLianBio7.59%PASGPassage Bio5.00%QTTBQ32 Bio40.00%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIANLianBio110108.06 million99.86 millionNot OptionablePASGPassage Bio13062.15 million59.11 millionOptionableQTTBQ32 Bio3912.20 million10.22 millionN/ASNGXSoligenix203.26 million2.44 millionNot OptionableSNGX, QTTB, LIAN, and PASG HeadlinesRecent News About These CompaniesSoligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer TrialMay 24, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial ResultsMay 20, 2025 | theglobeandmail.comSNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…May 13, 2025 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.May 7, 2025 | finance.yahoo.comSoligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 30, 2025 | msn.comSolgenix shares rise on positive skin cancer treatment resultsApril 24, 2025 | investing.comFireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.April 24, 2025 | msn.comEQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 24, 2025 | markets.businessinsider.comSNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…April 15, 2025 | msn.comPositive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 WeeksApril 14, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma TreatmentApril 3, 2025 | theglobeandmail.comSoligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick FactsMarch 27, 2025 | nasdaq.comSoligenix selects IBN to spearhead corporate communicationsMarch 26, 2025 | markets.businessinsider.comSNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…March 26, 2025 | msn.comSoligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 26, 2025 | medindia.netIBN Initiates Coverage of Soligenix Inc.March 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNGX, QTTB, LIAN, and PASG Company DescriptionsLianBio NASDAQ:LIAN$0.36 0.00 (0.00%) As of 05/27/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Passage Bio NASDAQ:PASG$0.36 +0.00 (+0.47%) Closing price 04:00 PM EasternExtended Trading$0.36 0.00 (-1.33%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Q32 Bio NASDAQ:QTTB$1.83 +0.15 (+8.93%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.01 (-0.27%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Soligenix NASDAQ:SNGX$1.93 +0.02 (+1.05%) Closing price 03:59 PM EasternExtended Trading$1.92 -0.01 (-0.52%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings ThredUp Stock Reverses on AI Buzz, Eyes Double-Digit Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
